ICECURE MEDICAL LTD
ICCMNASDAQTrading Snapshot
- Day Range
- $1.65 – $1.68
- 52-Week Range
- $1.65 – $42.00
- Volume
- $3.09B
- Avg Volume
- $3.33B
- Shares Outstanding
- 3.4M
- Next Earnings
- Nov 24, 2026
Fundamentals Snapshot
- Annual Revenue
- $3M
- Last Q Revenue
- $907,000
- P/E Ratio
- —
- P/S Ratio
- 1.4x
- EPS (TTM)
- $-6.73
- Dividend Yield
- —
- Dilution (1yr)
- +31.0%
Why Investors Own ICCM
- ✓High-growth profile — revenue up +49.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 45% gross margin and 12% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ICECURE MEDICAL LTD
ICCM
StockOtter · stockotter.spaceAbout ICECURE MEDICAL LTD
IceCure Medical Ltd develops and markets minimally invasive cryoablation therapies for the women's health and oncology markets. The company is headquartered in Caesarea, Israel.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Reviewing IceCure Medical (NASDAQ:ICCM) & Precision Optics (NASDAQ:POCI)
Precision Optics (NASDAQ: POCI - Get Free Report) and IceCure Medical (NASDAQ: ICCM - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on t
IceCure Secures China NMPA Approval for ProSense Cryoablation System
ICCM's NMPA approval for ProSense opens China to commercialization, expanding its global regulatory footprint and long-term revenue opportunity.
IceCure Medical Receives Regulatory Approval to Market ProSense® in China
CAESAREA, Israel, Sept. 10, 2026 /PRNewswire/ -- IceCure Medical Ltd.
IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands
Agreement expands ProSense® commercialization in the Netherlands as cryoablation advances to Phase III in the Netherlands-based independent THERMAC breast cancer cryoablation trial after achieving the highest complete ab
West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation
Patients are expected to enroll in the post-marketing study in the coming weeks, following approval from the Institutional Review Board of West Cancer Center & Research Institute in Germantown, TN CAESAREA, Israel, Aug.
IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation
New review by leading U.S. experts highlights ProSense® FDA marketing authorization, updated American Society of Breast Surgeons guidelines, and encouraging outcomes from the five-year ICE3 clinical trial while a second